|
|
楼主 |
发表于 2025-1-9 17:21:59
|
显示全部楼层
还统计少了，华西医院牵头是25项
) P9 [% X) W1 A01.Risk factors of complications after inguinal lymph node dissection in patients with penile cancer.
# a1 Q8 S( X; p02.Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor.
# k' Z. C. Y: e" g1 e03.Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract urothelial carcinoma: A study focusing on temporal heterogeneity./ ?7 U3 Y; v, D H. V( c+ A, L
04.The impact of neoadjuvant therapy on the formation of tertiary lymphatic structures and the distinct prognosis in prostate cancer.
: y! L9 c% @4 c1 K05.Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: Results from a large-scale longitudinal cohort study.
) `6 N2 g1 j- j% t/ [- K+ K c06.Survival impact of concomitant squamous differentiation in upper tract urothelial carcinoma patients receiving adjuvant chemotherapy.
. u" y0 M; e" X& b7 B07.Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines., j- Z* q, v6 q4 J8 q
08.Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis.
( j J3 k- F, j" y. s09.Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study.
0 m5 E9 ~ d/ H/ N$ F" j10.Interpretable machine learning for prostate biopsy: Cohort study.
# L& R. ? m% q9 p11.Genomic features of prostate cancer patients with and without ductal adenocarcinoma (DA) based on liquid biopsy.
* r7 ?+ Z {8 D5 P9 R12.Clinicopathological features and prognosis of MED15-TFE3 rearrangement renal cell carcinoma: An updated report.6 |1 |5 s$ v* J" F
13.Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).! t# K2 K! ?! Q$ R+ @9 G4 N5 O R
14.A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).
4 `0 y, J% y7 G6 I" R' `15.VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy.
% p+ F9 g; \# g0 r16.Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study.. L6 d) v0 Z$ G! h" ?: u
17.Kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: A pilot study combining endoscopic thulium laser ablation with perioperative disitamab vedotin and immune checkpoint inhibitors.
! N6 N* X: X1 E, E' C. x6 G% j18.Comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of localized high-risk upper tract urothelial carcinoma: A potential paradigm shift.
5 j1 @& p, p1 u2 l$ P9 d6 q0 i N; @19.Efficacy of systemic treatments for advanced non-clear cell renal cell carcinoma: A single-arm systematic review and meta-analysis.
# s7 [; s" \2 `( |4 {; z20.The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer.5 c' V7 [( Z) s' @8 A% ~
21.Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021.+ M: [/ t& ~% }* w& J8 l
22.Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis.
) o( f5 d1 V: x0 o23.Assessment of the proficiency of ChatGPT-4o in an image-based robot-assisted radical prostatectomy scenario.3 T5 y' m1 L O9 k m# _3 ]
24.The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis.
! {, {# ^! P3 A& _" u x25.Global and regional burden of kidney cancer: Analysis and future predictions based on GBD data from 1990 to 2021.1 u) l$ F; k Y# W9 c
|
|
发表于 2025-1-9 15:59:44
发表于 2025-1-9 17:01:32
看年内重离子质子医院投运后，能否发起追赶
